Diabetes
Commentary
Whole-person care: Our foundation, our future
We can no longer go “halfway” into whole-person care.
From the Journals
Peripheral neuropathy tied to mortality in adults without diabetes
The condition is underrecognized and associated with poor outcomes, findings of a new study suggest.
From the Journals
Prioritize COVID-19 vaccination in both types of diabetes, say docs
The study is the first to prospectively evaluate COVID-19 severity factors and death in people with type 1 and type 2 diabetes separately.
Commentary
Are we shortchanging patients with obesity?
Recent studies suggest that patients are capable of greater weight loss than doctors might be giving them credit for. We can help more people...
From the Journals
Diabetic retinopathy may predict greater risk of COVID-19 severity
“Our study reports the first description of diabetic retinopathy as a potential risk factor for poor COVID-19 outcomes,” said the authors of a new...
Feature
Noninvasive, low-cost CGM for type 2 diabetes coming in U.S. and EU
Neumara Medical’s SugarBEAT device plus digital coaching aims to reverse, or at least better manage, type 2 diabetes and should be available soon...
Feature
Patient health suffers amid pandemic health care shortages
More than half of clinician respondents to a survey said they saw a decline in patient health because of delayed or inaccessible care.
From the Journals
New study pinpoints how Mediterranean diet reduces diabetes risk
Health care professionals should recognize the importance of weight loss in those older than 60 years and include them in programs to treat...
Conference Coverage
Metformin improves most outcomes for T2D during pregnancy
But the drug was associated with an increased risk of small-for-gestational-age babies.
From the Journals
Golimumab preserves insulin production in type 1 diabetes
For newly diagnosed patients, injections of the monoclonal antibody every 2 weeks preserved C-peptide levels and reduced required insulin doses at...
Conference Coverage
Finerenone’s heart benefits hold up in T2D patients without CVD
In the FIDELIO-DKD trial, cardiovascular benefits from a nonsteroidal mineralocorticoid antagonist held, regardless of CVD history, in T2D...